title: [Hemodilution in treatment of intrauterine dystrophy].
abstract: It was the aim of the study to show that HES (Hydroxy-Ethyl-Starch) in intrauterine dystrophy identified by ultrasonography can increase fetal growth. Twenty pregnant women were treated in two groups (outpatients versus inpatients). Clinically, the result was satisfying.
authors.affiliation: Landesfrauenklinik Linz.
authors.forename: M
authors.initials: M
authors.lastname: Bsteh
authors.forename: G
authors.initials: G
authors.lastname: Tews
authors.forename: D
authors.initials: D
authors.lastname: John
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D001724:Birth Weight; D005260:Female; D005317:Fetal Growth Retardation / Q000000981:diagnostic imaging / Q000628:therapy*; D005500:Follow-Up Studies; D006438:Hemodilution; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D007231:Infant, Newborn; D008875:Middle Aged; D010343:Patient Admission; D011247:Pregnancy; D014463:Ultrasonography
chemical_list: D006895:Hydroxyethyl Starch Derivatives